Maxim Group analyst Jason McCarthy assigned a Buy rating to Omeros (OMER) yesterday and set a price target of $25.00. The company’s shares closed last Tuesday at $18.43.
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 29.5% and a 38.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Monopar Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Omeros with a $25.00 average price target, which is a 43.8% upside from current levels. In a report issued on April 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $32.00 price target.
See today’s analyst top recommended stocks >>
Omeros’ market cap is currently $1.15B and has a P/E ratio of -7.40. The company has a Price to Book ratio of -9.13.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OMER in relation to earlier this year. Most recently, in February 2021, Peter Demopulos, a Director at OMER bought 10,000 shares for a total of $49,150.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
